A 16-week randomized trial found combined training lowered GLP-1 and amylin and raised DPP-4 in adults with type 2 diabetes and overweight, without a demonstrated glycaemic benefit. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
A randomized trial testing whether a patient previsit activation handout, added to physician academic detailing, increases diabetes medication deprescribing in adults 75 and older. PICO summary and expert commentary.
An exploratory open-label RCT found imeglimin and metformin lowered HbA1c similarly, but only imeglimin raised insulin and GIP secretion. PICO summary and expert commentary.
Replacing mealtime insulin with weekly semaglutide missed its primary glycaemic target (90% vs 75%, p=0.18) but cut weight and insulin dose in this small open-label trial. PICO summary and expert commentary.
A prespecified STRIDE subgroup analysis examined whether once-weekly semaglutide 1.0 mg improves walking distance consistently across diabetes characteristics in 792 adults with symptomatic PAD and type 2 diabetes. PICO summary and expert commentary.
A phase 1 first-in-human study of the oral GLP-1 receptor agonist ECC5004/AZD5004 in healthy volunteers and T2DM patients found it well tolerated with early dose-dependent glucose and weight signals. PICO summary and expert commentary.
A 6-month randomised trial in older adults with type 2 diabetes found home telemedicine plus Health Belief Model education cut HbA1c by 0.42% more than usual care. PICO summary and expert commentary.
An oral GLP-1 receptor agonist lowered HbA1c and body weight in phase 2 but was halted early after transaminase elevations ended its development. PICO summary and expert commentary.
A post-hoc EXSCEL analysis testing whether baseline ejection fraction modifies the effect of once-weekly exenatide on heart failure hospitalisation in type 2 diabetes. PICO summary and expert commentary.
A Sanofi-sponsored post hoc analysis of the LixiLan-L-CN trial reports that iGlarLixi lowered residual hyperglycaemia more than insulin glargine alone in Chinese adults with type 2 diabetes. PICO summary and expert commentary.